Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

ENDRA Life Sciences Reports $159,944 Second-Quarter 2026 Net Income

None

ENDRA Life Sciences (NDRA) reported net income of $159,944 for the second quarter ended June 30, 2026, compared with a net loss of $1.23 million a year earlier. Total other income was $1.64 million, including realized and unrealized gains on digital assets.

The company also entered a definitive merger agreement with Noble Africa, with closing expected in the fourth quarter of 2026 subject to stockholder, regulatory and other customary approvals.

  • Second-quarter operating expenses were $1.48 million, compared with $1.30 million in the prior-year period.
  • Research and development expense was $233,665, down from $381,061 a year earlier.
  • Cash used in operations was approximately $0.9 million, compared with approximately $1.1 million in the second quarter of 2025.
  • As of June 30, 2026, cash totaled $1.74 million, restricted cash was $3.80 million, and digital assets were $1.90 million.
  • The proposed transaction includes a private placement expected to generate approximately $50 million in gross proceeds upon concurrent closing.
EARLY ACCESS
Receive NDRA Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$NDRA Hedge Fund Activity

We have seen 4 institutional investors add shares of $NDRA stock to their portfolio, and 5 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles